ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Oncept IL-2 lyophilisate and solvent for suspension for injection for cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

After reconstitution, each 1 ml dose contains:

Active substances:
Canarypox virus, strain vCP1338, expressing feline interleukin-2 gene, live.....$\geq 10^{6.0}$ $EAID^{1}_{50}$

[1] $EAID_{50}$: ELISA infectious dose 50%.

Excipients:

Qualitative composition of excipients and other constituents
Lyophilisate:
Sucrose
Collagen hydrolysate
Casein hydrolysate
Sodium chloride
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Solvent:
Water for injections

Lyophilisate: whitish.
Solvent: clear colourless liquid.

3. CLINICAL INFORMATION

3.1 Target species

Cats.

3.2 Indications for use for each target species

Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2 - 5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.

3.3 Contraindications

None.

3.4 Special warnings

Use of the recommended mode of administration in 5 injection points is important for achieving efficacy of the product; injection in 1 point may lead to reduced efficacy (see section 3.9).

Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section 3.9.

Efficacy has not been tested in cats with metastasis or lymph node involvement.

As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance.

Efficacy of the treatment has not been investigated beyond 2 years following treatment.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Canarypox recombinants are known to be safe for humans. Mild local and/or systemic adverse events related to the injection itself may be observed transitorily. Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cats:

Very common (>1 animal / 10 animals treated):	Injection site pain[1] Injection site swelling[1] Injection site scratching[1]
Common (1 to 10 animals / 100 animals treated):	Apathy[2] Elevated temperature[2,3]

[1] Moderate, usually disappears spontaneously within 1 week.
[2] Transient.
[3] Above 39.5 °C.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

3.9 Administration routes and dosage

Subcutaneous use.

After reconstitution of the suspension shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.

Treatment course: 4 administrations at 1-week intervals (day 0, day 7, day 14, day 21) followed by 2 administrations at 2-week intervals (day 35, day 49).

Start the treatment course the day before radiation therapy, preferably within one month after surgical excision.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, erythema or slight pain, and in some cases, heat at the injection site) may occur.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QL03AX90.

The vaccine strain vCP1338 is a recombinant canarypox virus expressing feline interleukin-2 (IL-2). The virus expresses the IL-2 gene at the inoculation site, but does not replicate in the cat.

Oncept IL-2 injected into the tumour bed thus delivers *in situ* a low dose of feline interleukin-2, which stimulates antitumour immunity while avoiding toxicity associated with systemic treatment. Specific mechanisms by which immunostimulation induces anti-tumoural activity are not known.

In a randomised clinical study, cats from different origins presenting a fibrosarcoma without metastasis or lymph node involvement were included in two groups, one receiving the reference treatment – surgery and radiotherapy – and the other receiving Oncept IL-2 in addition to surgery and radiotherapy. After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days). Oncept IL-2 treatment reduced the risk of relapse, from 6 months after the start of treatment, by approximately 56% after 1 year and 65% after 2 years, compared to the control group.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after reconstitution: use immediately.

5.3 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Store in the original package.
Protect from light.
Do not freeze.

5.4 Nature and composition of immediate packaging

Type I glass vial with a butyl elastomer closure, sealed with an aluminium cap.

Cardboard box of 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/13/150/001

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 03/05/2013

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box of 6 vials of lyophilisate and 6 vials of solvent

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Oncept IL-2 lyophilisate and solvent for suspension for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Per 1 dose:
Canarypox virus, strain vCP1338, expressing feline interleukin-2 gene, live.....$\geq 10^{6.0}$ $EAID_{50}$

3. PACKAGE SIZE

Lyophilisate: 6 x 1 dose
Solvent: 6 x 1 ml

4. TARGET SPECIES

Cats

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {dd/mm/yyyy}
Once reconstituted use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Store in the original package.
Protect from light.
Do not freeze.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH

14. MARKETING AUTHORISATION NUMBERS

EU/2/13/150/001

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Lyophilisate vial

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Oncept IL-2 lyophilisate

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 dose

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {dd/mm/yyyy}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Solvent vial

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Oncept IL-2 solvent

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {dd/mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Oncept IL-2 lyophilisate and solvent for suspension for injection for cats

2. Composition

After reconstitution, each 1 ml dose contains:

Canarypox virus, strain vCP1338, expressing feline interleukin-2 gene, live.....$\geq 10^{6.0}$ $EAID^{1}_{50}$

[1] $EAID_{50}$: ELISA infectious dose 50%.

Lyophilisate: whitish.
Solvent: clear colourless liquid.

3. Target species

Cats.

4. Indications for use

Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.

5. Contraindications

None.

6. Special warnings

Use of the recommended mode of administration in 5 injection points is important for achieving efficacy of the product; injection in 1 point may lead to reduced efficacy (see section “Dosage for each species, routes and method of administration”).
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section “Dosage for each species, routes and method of administration”.
Efficacy has not been tested in cats with metastasis or lymph node involvement.
As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance.
Efficacy of the treatment has not been investigated beyond 2 years following treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Canarypox recombinants are known to be safe for humans. Mild local and/or systemic adverse events related to the injection itself may be observed transitorily. Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:
After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, redness or slight pain, and in some cases, heat at the injection site) may occur.

Major incompatibilities:
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.

7. Adverse events

Cats:

Very common (> 1 animal / 10 animals treated): Injection site pain[1], injection site swelling[1], injection site scratching[1].
Common (1 to 10 animals / 100 animals treated): Apathy[2], elevated temperature[2,3].

[1] Moderate, usually disappears spontaneously within 1 week.
[2] Transient.
[3] Above 39.5 °C.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

Subcutaneous use.

Treatment course: 4 administrations at 1-week intervals (day 0, day 7, day 14, day 21) followed by 2 administrations at 2-week intervals (day 35, day 49).

Start the treatment course the day before radiation therapy, preferably within one month after surgical excision.

9. Advice on correct administration

After reconstitution: clear homogeneous suspension.

After reconstitution of the suspension, shake gently and administer subcutaneously five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.



10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).
Store in the original package.
Protect from light.
Do not freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp.
Shelf life after reconstitution: use immediately.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/13/150/001

Cardboard box of 6 x 1 dose of lyophilisate and 6 x 1 ml of solvent.

15. Date on which the package leaflet was last revised

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
Germany

Manufacturer responsible for batch release:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint-Priest
France

Local representatives and contact details to report suspected adverse events:

België/Belgique/Belgien
Boehringer Ingelheim Animal Health Belgium SA
Avenue Arnaud Fraiteurlaan 15-23,
BE-1050 Bruxelles/Brussel/Brüssel
Tél/Tel: + 32 2 773 34 56

Република България
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer Gasse 5-11
AT-1121 Виена
Tel: +359 2 958 79 98

Česká republika
Boehringer Ingelheim spol. s r.o.
Purkyňova 2121/3
CZ - 110 00, Praha 1
Tel: +420 234 655 111

Danmark
Boehringer Ingelheim Animal Health Nordics A/S
Weidekampsgade 14
DK-2300 København S
Tlf: + 45 3915 8888

Deutschland
Boehringer Ingelheim Vetmedica GmbH
DE-55216 Ingelheim/Rhein
Tel: 0800 290 0 270

Lietuva
Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Dr. Boehringer Gasse 5-11
AT-1121 Viena
Tel: +370 5 2595942

Luxembourg/Luxemburg
Boehringer Ingelheim Animal Health Belgium SA
Avenue Arnaud Fraiteurlaan 15-23,
BE-1050 Bruxelles/Brussel/Brüssel
Tél/Tel: + 32 2 773 34 56

Magyarország
Boehringer Ingelheim RCV GmbH & Co KG
Magyarországi Fióktelep
Lechner Ö. Fasor 10.
HU-1095 Budapest
Tel: +36 1 299 8900

Malta
Boehringer Ingelheim Vetmedica GmbH
DE-55216 Ingelheim/Rhein
Tel: +353 1 291 3985

Nederland
Boehringer Ingelheim Animal Health Netherlands B.V.
Basisweg 10
NL-1043 AP Amsterdam
Tel: +31 20 799 6950

Eesti
Boehringer Ingelheim RCV GmbH & Co KG
Eesti filiaal
Dr. Boehringer Gasse 5-11
AT-1121 Viin
Tel: +372 612 8000

Ελλάδα
Boehringer Ingelheim Vetmedica GmbH
DE-55216 Ingelheim/Rhein
Τηλ: +30 2108906300

España
Boehringer Ingelheim Animal Health España, S.A.U.
Prat de la Riba, 50
ES-08174 Sant Cugat del Vallès (Barcelona)
Tel: +34 93 404 51 00

France
Boehringer Ingelheim Animal Health France SCS
29, avenue Tony Garnier
FR-69007 Lyon
Tél : +33 4 72 72 30 00

Hrvatska
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer Gasse 5-11
AT-1121 Beč
Tel: +385 1 2444 600

Ireland
Boehringer Ingelheim Vetmedica GmbH
DE-55216 Ingelheim/Rhein
Tel: +353 1 291 3985

Ísland
Vistor
Hörgatún 2
IS-210 Garðabær
Sími: + 354 535 7000

Italia
Boehringer Ingelheim Animal Health Italia S.p.A.
Via Vezza d'Oglio, 3
IT-20139 Milano
Tel: +39 02 53551

Norge
Boehringer Ingelheim Animal Health Nordics A/S
Weidekampsgade 14
DK-2300 København S
Tlf: +47 66 85 05 70

Österreich
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer Gasse 5-11
AT-1121 Wien
Tel: +43 1 80105-6880

Polska
Boehringer Ingelheim Sp. z o.o.
ul. Józefa Piusa Dziekonskiego 3
PL-00-728 Warszawa
Tel.: + 48 22 699 0 699

Portugal
Boehringer Ingelheim Animal Health Portugal, Unipessoal, Lda.
Avenida de Pádua, 11
PT-1800-294 Lisboa
Tel: +351 21 313 5300

România
Boehringer Ingelheim RCV GmbH & Co KG
Sucursala Bucureşti
Dr. Boehringer Gasse 5-11
AT-1121 Viena
Tel: +40 21 302 28 00

Slovenija
Boehringer Ingelheim RCV GmbH & Co KG
Podružnica Ljubljana
Dr. Boehringer Gasse 5-11
AT-1121 Dunaj
Tel: +386 1 586 40 00

Slovenská republika
Boehringer Ingelheim RCV GmbH & Co KG, o.z.
Dr. Boehringer Gasse 5-11
AT-1121 Viedeň
Tel: +421 2 5810 1211

Suomi/Finland
Vetcare Oy
PB 99
FI-24101 Salo
Puh/Tel: + 358 201443360

Κύπρος
Boehringer Ingelheim Vetmedica GmbH
DE-55216 Ingelheim/Rhein
Τηλ: +30 2108906300

Latvija
Boehringer Ingelheim RCV GmbH & Co KG
Latvijas filiāle
Dr. Boehringer Gasse 5-11
AT-1121 Vīne
Tel: +371 67 240 011

Sverige
Boehringer Ingelheim Animal Health Nordics A/S
Weidekampsgade 14
DK-2300 Köpenhamn S
Tel: +46 (0)40-23 34 00

United Kingdom (Northern Ireland)
Boehringer Ingelheim Vetmedica GmbH
DE-55216 Ingelheim/Rhein
Tel: +353 1 291 3985

17. Other information

The vaccine strain vCP1338 is a recombinant canarypox virus expressing feline interleukin-2 (IL-2). The virus expresses the IL-2 gene at the inoculation site, but does not replicate in the cat.
Oncept IL-2 injected into the tumour bed thus delivers *in situ* a low dose of feline interleukin-2, which stimulates antitumour immunity while avoiding toxicity associated with systemic treatment.
Specific mechanisms by which immunostimulation induces anti-tumoural activity is not known.

In a randomized clinical study, cats from different origins presenting a fibrosarcoma without metastasis or lymph node involvement were included in two groups, one receiving the reference treatment – surgery and radiotherapy – and the other receiving Oncept IL-2 in addition to surgery and radiotherapy. After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days). Oncept IL-2 treatment reduced the risk of relapse, from 6 months after the start of treatment, by approximately 56% after 1 year and 65% after 2 years, compared to the control group.